In order to analyze whether anti-glaucoma medications affected the experimental results, we divided AACG patients with high IOP into “drugs” group and “no drug” group, and found that there was not significantly difference in concentrations of bioactive TGFβ2 and SFRP1 between these two groups (Additional file 2: Figure S2). Here, SFRP1 is linked to glaucoma.